Profile data is unavailable for this security.
About the company
Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company focused on discovering, developing, and potentially commercializing small molecule-based medicines that modulate the activity and stability of pathologically altered proteins. The Company has established a pipeline of orally available small molecule inhibitors for various indications, focused on oral small molecule-based therapeutics with a differentiated mode of action for treating diseases with inflammatory and/or fibrotic components, such as chronic diseases of the kidney or liver. It focuses on chronic kidney disease (CKD), and more precisely- are initially targeting stage 3b and worse diabetic kidney disease (DKD). In addition to developing small molecule-based medicines, the Company is also pursuing antibody-based approaches for Alzheimer’s disease (AD).
- Revenue in EUR (TTM)0.00
- Net income in EUR-12.48m
- Incorporated--
- Employees14.00
- LocationVivoryon Therapeutics NVWeinbergweg 22HALLE 06120GermanyDEU
- Phone+49 3 455559900
- Fax+49 3 455559901
- Websitehttps://www.vivoryon.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| genOway SA | 20.95m | 1.29m | 30.49m | 148.00 | 16.14 | 1.13 | 7.54 | 1.46 | 0.1487 | 0.1487 | 2.42 | 2.12 | 0.594 | 0.8797 | 3.69 | 146,514.10 | 3.65 | 2.10 | 4.72 | 2.91 | 94.91 | 94.80 | 6.14 | 3.76 | 2.21 | -- | 0.4407 | -- | 10.04 | 18.46 | 16.79 | -- | 15.88 | -- |
| Mabion SA | 3.51m | -14.07m | 31.45m | 204.00 | -- | 1.89 | -- | 8.95 | -3.67 | -3.67 | 0.9164 | 4.33 | 0.0988 | 8.10 | 27.25 | 72,602.94 | -39.56 | 0.5366 | -54.81 | 1.06 | -178.55 | 58.34 | -400.37 | 0.9643 | 0.2276 | -- | 0.04 | -- | -54.50 | -- | -115.35 | -- | 6.00 | -- |
| Arecor Therapeutics PLC | 5.82m | -9.32m | 31.48m | 37.00 | -- | 9.58 | -- | 5.41 | -0.2208 | -0.2208 | 0.1368 | 0.0756 | 0.6482 | 18.58 | 1.93 | 136,783.80 | -103.79 | -53.69 | -187.88 | -68.26 | -2.45 | -- | -160.13 | -248.39 | 2.00 | -- | 0.0571 | -- | 10.50 | -- | -19.66 | -- | -- | -- |
| Zelluna ASA | 0.00 | -12.49m | 37.30m | 26.00 | -- | 4.90 | -- | -- | -7.10 | -7.10 | 0.00 | 3.27 | 0.00 | -- | -- | -- | -128.29 | -44.36 | -165.31 | -49.63 | -- | -- | -- | -- | -- | -- | 0.008 | -- | -- | -- | 30.02 | -- | -41.59 | -- |
| Molecure SA | 1.21m | -5.80m | 37.45m | 71.00 | -- | 1.76 | -- | 30.87 | -1.20 | -1.20 | 0.2493 | 4.34 | 0.0553 | -- | 7.01 | 50,119.41 | -26.42 | -3.15 | -27.53 | -3.30 | 51.48 | 93.34 | -477.67 | -15.45 | -- | -- | 0.0588 | -- | -40.47 | 278.20 | -10.27 | -- | 12.49 | -- |
| Poolbeg Pharma PLC | 0.00 | -6.57m | 37.68m | 10.00 | -- | 2.75 | -- | -- | -0.0114 | -0.0114 | 0.00 | 0.0171 | 0.00 | -- | -- | 0.00 | -45.01 | -- | -46.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -47.29 | -- | -- | -- |
| Ascelia Pharma AB | 0.00 | -7.19m | 39.06m | 11.00 | -- | 4.20 | -- | -- | -0.693 | -0.693 | 0.00 | 0.7777 | 0.00 | -- | -- | -- | -60.31 | -54.24 | -85.44 | -64.44 | -- | -- | -- | -- | -- | -31.70 | 0.0097 | -- | -- | -- | 4.72 | -- | -32.17 | -- |
| Fermentalg SA | 12.78m | -11.54m | 39.22m | 63.00 | -- | 1.38 | -- | 3.07 | -0.1242 | -0.1242 | 0.1353 | 0.3156 | 0.2472 | 7.91 | 3.29 | 199,734.40 | -17.09 | -18.10 | -21.17 | -20.59 | 20.94 | 25.51 | -69.14 | -147.66 | 1.83 | -- | 0.2368 | -- | 183.32 | 43.52 | 8.99 | -- | -4.91 | -- |
| Sequana Medical NV | 0.00 | -51.85m | 41.06m | 48.00 | -- | -- | -- | -- | -1.24 | -1.24 | 0.00 | -0.6848 | 0.00 | 1.61 | -- | 0.00 | -408.93 | -201.76 | -- | -- | -- | -427.70 | -- | -4,902.24 | 0.1559 | -0.5006 | 18.59 | -- | -85.19 | -35.84 | -37.13 | -- | -22.17 | -- |
| Vivoryon Therapeutics NV | 0.00 | -12.48m | 41.46m | 14.00 | -- | 11.55 | -- | -- | -0.4784 | -0.4784 | 0.00 | 0.1213 | 0.00 | -- | -- | 0.00 | -106.64 | -73.24 | -122.38 | -81.05 | -- | -- | -- | -1,487.00 | -- | -- | 0.0221 | -- | 100.00 | -- | 27.43 | -- | -46.82 | -- |
| Medivir AB | 375.69k | -7.34m | 46.54m | 10.00 | -- | 1.89 | -- | 123.88 | -0.6789 | -0.6789 | 0.0348 | 0.5831 | 0.0238 | -- | 0.9374 | 398,400.00 | -46.44 | -31.75 | -69.67 | -38.14 | -- | -- | -1,953.24 | -740.12 | -- | -70.04 | 0.00 | -- | -54.36 | -16.77 | -38.06 | -- | -- | -- |
| Herantis Pharma Oyj | 0.00 | -5.45m | 48.75m | 13.00 | -- | 25.90 | -- | -- | -0.2417 | -0.2417 | 0.00 | 0.0726 | 0.00 | -- | -- | 0.00 | -124.50 | -81.63 | -166.61 | -107.95 | -- | -- | -- | -- | -- | -17.91 | 0.6101 | -- | -- | -- | -1,865.03 | -- | -- | -- |
| Anatolia TaniveBytklj Unli Ar Ge SiveTiA | 12.12m | -5.87m | 51.22m | 247.00 | -- | 1.58 | -- | 4.23 | -1.38 | -1.38 | 2.85 | 7.63 | 0.3282 | 0.7324 | 4.92 | 2,815,434.00 | -15.90 | 5.77 | -17.08 | 6.10 | 63.69 | 80.17 | -48.44 | 15.31 | 2.09 | -- | 0.0869 | -- | 54.06 | 91.00 | -10.92 | -- | 96.35 | -- |
Data as of Feb 17 2026. Currency figures normalised to Vivoryon Therapeutics NV's reporting currency: Euro EUR
3.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Matejka & Partner Asset Management GmbHas of 29 Aug 2025 | 529.56k | 1.79% |
| GVC Gaesco Gesti�n SGIIC SAas of 31 Dec 2025 | 345.50k | 1.17% |
| amandea Verm�gensverwaltung AGas of 30 Sep 2025 | 100.00k | 0.34% |
| LFG+ZEST SAas of 31 Mar 2025 | 0.00 | 0.00% |
| Azimut Capital Management SGR SpAas of 31 Oct 2024 | 0.00 | 0.00% |
| ETHENEA Independent Investors SAas of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 29 Aug 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
